SAN DIEGO / Sep 26, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. Management will hold a conference call to review the company's third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.
To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-1647 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
| Last Trade: | US$75.82 |
| Daily Change: | 0.56 0.74 |
| Daily Volume: | 3,130,216 |
| Market Cap: | US$29.620B |
December 17, 2024 November 19, 2024 October 24, 2024 September 04, 2024 August 28, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
